Lexeo Therapeutics Inc. (LXEO) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, LXEO scores 33 out of 100, a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars. The fundamental cash engine pillar scores 6 out of 20, reflecting ROIC of -35% and an FCF yield of 0%. The whale/13F flow pillar scores 5 out of 20, covering institutional accumulation and options positioning. The insider conviction pillar scores 5 out of 20, covering SEC Form 4 and Congressional PTR cluster flow. The macro regime fit pillar scores 7 out of 20, reflecting a beta of 1.0 and sector sensitivity. The forensic balance sheet pillar scores 10 out of 20, reflecting an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5.

For a prospective investor evaluating the stock today, the pillar profile points to a company that is not yet generating returns on capital or free cash flow, so the investment case rests on non-operating drivers rather than earnings power. The insider and flow pillars are weak, which means the score does not rely on strong signs of conviction from insiders or large holders. The balance-sheet pillar is the most supportive, though a Piotroski F-Score of 2 out of 9 is a weak reading. The main upside driver implied by the data is any improvement in the company's cash-generation trajectory, but the source data does not quantify when or whether that would occur. Valuation tradeoffs are difficult to assess because P/E, EV/EBITDA, and EPS are not available in source data. The overall investor implication is that the rating treats LXEO as high forensic risk with limited near-term support from the operating business.

Lexeo Therapeutics Inc. (LXEO) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile. The profile reports a market capitalization of $0.3B. Not available in source data: customer base, product or revenue model, and how the company monetizes its activities. Per the SEC financials, reported revenue is $0.0M in each of the periods shown.

Per the SEC financials, the company reported operating losses and negative free cash flow across the periods shown, with net losses widening from $-66.4M in FY 2023 to $-100.0M in FY 2025. Per the market data, gross, operating, and net margins are each 0% and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the Roarable RQD rating, Debt/Equity is 0.5, and reported cash rose to $63.0M in FY 2025 from $35.0M in FY 2024.

Per the recent news feed, the headlines are dated within the past 15 hours of the data timestamp and are all tagged to LXEO. Key items include: participation in the Chardan Healthcare Conference; a Seeking Alpha slideshow on clinical assessment and unmet need in PKP2 arrhythmogenic cardiomyopathy; a GuruFocus report that JPMorgan Chase & Co acquired 4,573,701 shares of LXEO; an item citing seven people on gene therapy averaging over 4 points of neurological improvement after 3 years; and an invitation to an educational event on clinical endpoints and outcome measures in PKP2-ACM. Each feed item is labeled YELLOW with a MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Per the Butterfly Supply-Chain Graph, supply chain is NONE and there are no butterfly links or proprietary signals. Not available in source data: upstream suppliers, downstream customers, and sector correlation data. Investors should watch for the institutional accumulation signal in the news feed, the PKP2-ACM clinical discussion items, and the 52-week price range of $2.55 to $10.99, but the source data does not establish causal ripple effects from these.

• What is the company's revenue model, given zero reported revenue across the periods shown?
• What is the company's cash runway relative to its FY 2025 net loss of $-100.0M and FCF of $-99.0M?
• What drives the institutional accumulation referenced in the news feed, and what is the size of the reported positions beyond the single JPMorgan Chase headline?
• What are the terms and timing of any debt, given that debt figures are reported as N/A?
• What is the status and timeline of the clinical programs referenced in the news feed?